Otros idiomas Petros Pharmaceuticals, Inc.

Acciones

PTPI

US71678J2096

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 05/07/2024			Varia. Cinco días.	Varia. 1 de enero.
0,415 ^USD	-2,15 %		-9,29 %	-70,57 %

29/05	Petros Pharmaceuticals completa con exito un estudio formativo de factores humanos integrado en IA que demuestra una interaccion positiva con la aplicacion web disenada para el cambio a STENDRA(R) (avanafil) OTC	CI
15/05	Petros Pharmaceuticals, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch	30/05
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) OTC Switch	29/05
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	14/05
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	14/05
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication	14/05
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals	14/05
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals	14/05
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health	25/04
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health	24/04
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	23/04
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	23/04
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	16/04
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	16/04
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	02/04
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc	11/03
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	14/02
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?	06/02
Top Premarket Gainers	30/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Petros Pharmaceuticals, Inc.

Acciones

PTPI

US71678J2096

Otros idiomas

Filtros